It was described previously in esophageal, breast, lung, pancreatic, bladder, and colorectal cancers that NORAD functions as a potential oncogenic factor, suggesting that it may constitute a tumor biomarker, defining patient prognosis, predicting therapy response, and/or be used as a therapeutic target.16 This evidence concerns the gene NORAD and colorectal cancer.